REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.

Also called NCT06788535

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 204 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as a collaborator
Registry
  • NCT NCT06788535
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06788535. Allocation not applicable; no masking; primary purpose diagnostic. Start 2025-01-14 (actual); primary completion 2026-04-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
Acronym
REVEAL
Condition
Cardiac Amyloidosis
Intervention (Drug)
I-124 evuzamitide
Lead sponsor
Sharmila Dorbala (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct06788535
Content hash
f6250999f3f8481c5db2ae5a27049c4857b117edd979220719551618ab38bb56